Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elsa Bernard

Showing results (21-30 of 52) with videos related to

Pageof 6
Sort By:
Blood|August 4, 2025
A precision medicine approach to the myelodysplastic syndrome with isolated deletion 5q 50 years after its discoveryMarco Roncador, Elsa Bernard, Robert P Hasserjian, et al.
Research Square|April 24, 2023
The E592K variant of SF3B1 creates unique RNA missplicing and associates with high-risk MDS without ring sideroblastsIn Young Choi, Jonathan Ling, Jian Zhang, et al.
Blood Advances|February 11, 2021
Modulation of IL-6/STAT3 signaling axis in CD4+FOXP3- T cells represents a potential antitumor mechanism of azacitidineEleftheria Lamprianidou, Chryssoula Kordella, Anastasiya Kazachenka, et al.
Blood Advances|January 18, 2022
Patient-specific MDS-RS iPSCs define the mis-spliced transcript repertoire and chromatin landscape of SF3B1-mutant HSPCsGeorgios Asimomitis, André G Deslauriers, Andriana G Kotini, et al.
Leukemia|March 12, 2022
"Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)"Bengt Rasmussen, Gudrun Göhring, Elsa Bernard, et al.
Transplantation and Cellular Therapy|September 9, 2021
Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelomonocytic Leukemia: Clinical and Molecular Genetic Prognostic Factors in a Nordic PopulationEileen Wedge, Jakob Werner Hansen, Ingunn Dybedal, et al.
Blood Advances|May 17, 2024
The E592K variant of SF3B1 creates unique RNA missplicing and associates with high-risk MDS without ring sideroblastsIn Young Choi, Jonathan P Ling, Jian Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 27, 2023
Integrated Genomic and Transcriptomic Analysis Improves Disease Classification and Risk Stratification of MDS with Ring SideroblastsGabriele Todisco, Maria Creignou, Elsa Bernard, et al.
Journal of Internal Medicine|April 24, 2024
Early transfusion patterns improve the Molecular International Prognostic Scoring System (IPSS-M) prediction in myelodysplastic syndromesMaria Creignou, Elsa Bernard, Alessandro Gasparini, et al.
Nature Communications|August 8, 2022
Unified classification and risk-stratification in Acute Myeloid LeukemiaYanis Tazi, Juan E Arango-Ossa, Yangyu Zhou, et al.
Pageof 6

Showing results (21-30 of 52) with videos related to

Sort By:
Pageof 6
Blood|August 4, 2025
A precision medicine approach to the myelodysplastic syndrome with isolated deletion 5q 50 years after its discoveryMarco Roncador, Elsa Bernard, Robert P Hasserjian, et al.
Research Square|April 24, 2023
The E592K variant of SF3B1 creates unique RNA missplicing and associates with high-risk MDS without ring sideroblastsIn Young Choi, Jonathan Ling, Jian Zhang, et al.
Blood Advances|February 11, 2021
Modulation of IL-6/STAT3 signaling axis in CD4+FOXP3- T cells represents a potential antitumor mechanism of azacitidineEleftheria Lamprianidou, Chryssoula Kordella, Anastasiya Kazachenka, et al.
Blood Advances|January 18, 2022
Patient-specific MDS-RS iPSCs define the mis-spliced transcript repertoire and chromatin landscape of SF3B1-mutant HSPCsGeorgios Asimomitis, André G Deslauriers, Andriana G Kotini, et al.
Leukemia|March 12, 2022
"Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)"Bengt Rasmussen, Gudrun Göhring, Elsa Bernard, et al.
Transplantation and Cellular Therapy|September 9, 2021
Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelomonocytic Leukemia: Clinical and Molecular Genetic Prognostic Factors in a Nordic PopulationEileen Wedge, Jakob Werner Hansen, Ingunn Dybedal, et al.
Blood Advances|May 17, 2024
The E592K variant of SF3B1 creates unique RNA missplicing and associates with high-risk MDS without ring sideroblastsIn Young Choi, Jonathan P Ling, Jian Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 27, 2023
Integrated Genomic and Transcriptomic Analysis Improves Disease Classification and Risk Stratification of MDS with Ring SideroblastsGabriele Todisco, Maria Creignou, Elsa Bernard, et al.
Journal of Internal Medicine|April 24, 2024
Early transfusion patterns improve the Molecular International Prognostic Scoring System (IPSS-M) prediction in myelodysplastic syndromesMaria Creignou, Elsa Bernard, Alessandro Gasparini, et al.
Nature Communications|August 8, 2022
Unified classification and risk-stratification in Acute Myeloid LeukemiaYanis Tazi, Juan E Arango-Ossa, Yangyu Zhou, et al.
Pageof 6